3. GOOD HEALTH AND WELL-BEING

Shares of agilon health (NYSE:AGL) are down 12% following an analyst downgrade. – Best Stocks

Written by Amanda

Shares of agilon health (NYSE:AGL) are down 12% following an analyst downgrade.  Best Stocks

As a result of the decision by SVB Leerink to lower their price objective from $33.00 to $30.00, the share price of AGL dropped by 12% during trading on Friday. The SVB Leerink was recently rated “outperform,” indicating that investors anticipate the stock to do well. A monthly subscription to Agilon Health can be had for a cost ranging from $16.99 to $17.00. Compared to the daily average volume of trading, which is 1,576,864 shares, the total number of shares that changed hands during trading was 112,220, which is a drop of 93% from the daily average trading volume. Before that, the stock price had reached $19.31 when the market closed for the day.

A number of other equity research professionals recently published studies on the company’s stock. The most recent events are the primary focus of these papers. Goldman Sachs Group stated in a report that was made available to the public on September 12 that they intend to broaden the scope of their coverage to include Aggilon Health. They recommended that investors “buy” the stock and set its price objective at $38.00. The price objective that Truist Financial has placed on shares of Agilon Health has decreased from $33.00 to $29.00, as stated in a research report that was published on September 7. Goldman Sachs Group made their announcement public on September 12, saying they will increase their coverage to include Aggilon Health. They recommended that investors “buy” the stock and set its price objective at $38.00. In a research report published on September 7, Truist Financial lowered their price objective on shares of Agilon Health from $33.00 to $29.00. Despite this modification, they maintained that “buying” the stock was the best action. The Royal Bank of Canada announced, in a report that was made available to the general public on September 14, that they intend to broaden their scope of coverage to include Aglion Health. They graded the company as “outperforming” based on their forecast to “outperform” its price target of $33, which they had set. In a research report released on Monday, August 8, Wells Fargo & Company rated Agilon Health as “overweight” and increased their price target on shares of Agilon Health from $23.00 to $28.00. The report also stated that the price target was raised from $23.00 to $28.00. In a report published on Thursday, August 18, Agilon Health share prices were assigned a grade of “d+,” a tier below the previous rating of “c-,” which had been assigned by TheStreet. In contrast to the seven financial analysts who gave the stock a buy rating, only one of the analysts polled recommended maintaining the stock’s current holdings. The information from Bloomberg indicates that the recommendation for Agilon Health is a “Moderate Buy” and that the price target has been established at $30.57.
Benjamin Shaker, an insider at Agilon Health, sold 29,548 shares of the company’s stock on Thursday, October 20. This transaction was disclosed in other news regarding Agilon Health. The sale of the shares generated total revenue of $601,892.76 based on the weighted average price of $20.37 per share, which was determined by the price at which the shares were sold. Following the completion of the transaction, the company insider now directly owns 25,625 shares of the company. The current market value of these shares is estimated to be $521,981.25. The Securities and Exchange Commission was given legal documents about the transaction, which were subsequently uploaded to the SEC website after being provided to the SEC. On October 20, a company insider named Benjamin Shaker sold 29,548 shares of the company’s stock. This is just one of the many items that are relevant to this subject. The sale of the shares generated total revenue of $601,892.76 based on the weighted average price of $20.37 per share, which was determined by the price at which the shares were sold. After the completion of the transaction, the company insider now owns 25,625 shares of the company, which have a combined value of $521,981.25. You might find a filing that explains the transaction in greater detail on the Securities and Exchange Commission (SEC) website. Benjamin Kornitzer, an employee of the company with insider trading privileges, sold 5,396 shares of the company’s stock on August 23. The price of each share was set at $20.49, which resulted in a total sale volume of 110,564.04 dollars. The average price at which the shares were sold was $20.49. As a result of the purchase, the company insider now owns 10,853 shares of the company’s stock, which have an estimated value of $222,377.97. Disclosures that are related to the sale might be found in this section of the website. During the past ninety days, company insiders have been selling 11,410,216 company stock shares, resulting in a total sale price of $277,646,991. 3.30 company insiders own percent of the total shares currently outstanding.
Recently, several hedge funds and other significant investors have altered how they maintain their positions in AGL in light of recent developments. Through the first three months of 2018, Capital World Investors raised the proportion of Aegis Health stock owned by 1.3%. After making additional purchases of 456,437 shares during the relevant period, Capital World Investors now has a total of 36,322,390 shares of the company’s stock in their possession, giving it a value of $920,773,000. These shares were acquired during the period in question. During the second quarter, FMR LLC increased the proportion of Aegilon Health’s shares that it owns by 14.9%. FMR LLC purchased an additional 4,512,008 shares of the company’s stock during the most recent quarter, bringing its total number of shares of its stock to 34,862,287. Each share of the company’s stock has a value of $761,043,000. In the first three months of 2018, Wellington Management Group LLP saw an increase of 11.0% in the proportion of Aegis Health shares it owned. After making an additional purchase of 1,834,890 shares during the most recent quarter, Wellington Management Group LLP now has 18,578,035 shares. Based on the current market value of the company’s stock, the firm has a value of approximately $470,953,000. During the first three months of 2018, Vanguard Group Inc. increased the percentage of its holdings allocated to AIG by 1.4%. After purchasing an additional 177,239 shares during the most recent quarter, Vanguard Group Inc. now directly owns 13,235,600 shares of the company’s stock, which is $335,522,000. These shares were acquired during the most recent quarter. And finally, during the first three months of 2018, Capital Research Global Investors saw an increase of 18.4% in the amount of Agios Health stock it owned. Capital Research Global Investors is the owner of a total of 9,867,875 shares of the company’s stock. These shares have a combined value of $250,151,000 as a whole. The most recent fiscal quarter saw the purchase of an additional 1,536,506 shares, which led to an increase in ownership. This rise in ownership was brought about as a result of this.

The debt-to-equity ratio comes in at 0.04, the quick ratio is 2.65, the current ratio is also 2.65, and the quick ratio comes in at 2.65. The company’s current market value is 6.87 billion dollars, its PE ratio is -61.50, while its beta value is 0.93. The stock price is $22.03 at the level corresponding to 50 days, while the price is only $21.78 at the level corresponding to 200 days.
Agilon Health (NYSE: AGL) disseminated the findings of its most recent quarterly financial report on Thursday, August 4, making the announcement. The company reported earnings per share of $0.04 for the quarter, which fell short of the consensus estimate of $0.02 among market experts, who had predicted earnings per share of $0.02. The return on equity for Agilon Health was negative by 9.80 percentage points, and the company’s net margin was also negative by 4.99 percentage points. The actual amount of revenue brought in for the company during the quarter was $670.13 million, which is higher than the $648.74 million in revenue anticipated for the corporation throughout the quarter. The company incurred a loss equivalent to $0.06 per share in the same period the year before. Sell-side analysts forecast that Agilon Health, Inc. will generate a loss of 0.17 cents per share in earnings during the current financial year.

Primary care physicians are the ones on whom Agilon Health, Inc. relies to provide senior citizens in the United States with the myriad of medical treatments necessary for them. As of December 31 in 2021, it provided services to approximately 238,000 senior citizens. Of these, 186,300 were participants in the Medicare Advantage program, and 51,700 were recipients of Medicare fee-for-service.

Source: news.google.com

About the author

Amanda

Hi there, I am Amanda and I work as an editor at impactinvesting.ai;  if you are interested in my services, please reach me at amanda.impactinvesting.ai

Leave a Comment